Authors
Latest:
Dr Stone on the Investigation of Limited English Proficiency and PSA Screening Rates in Prostate CancerBenjamin V. Stone, MD, discusses clinical implications derived from a retrospective study on the effect of limited English proficiency on prostate-specific antigen screening rates in American men with prostate cancer, as well as the need to improve equitable access to PSA screening across academic and community centers.
Latest:
Renal Cell Carcinoma: Future Directions in CareLooking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.
Latest:
Immunotherapy for NSCLC: Clinical PearlsFinal takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
Latest:
Dr. LeBeau on the Potential Applicability of Shark Antibodies in Prostate CancerAaron LeBeau, PhD, discusses the potential wide applicability of shark antibodies in developing imaging and therapeutic strategies in prostate cancer.
Latest:
Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLCJorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.
Latest:
Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS MetastasesThomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
Latest:
Dr. O’Regan on the Development of Oral SERDs in Breast CancerRuth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.
Latest:
Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary CareA brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.
Latest:
What’s Coming Next in Relapsed/Refractory Multiple MyelomaKey opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Dr. Boutros on the Utility of Genetic Testing in Prostate CancerPaul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.
Latest:
Dr Iglesia on the COSMIC-312 Trial of Cabozantinib Plus Atezolizumab in HCCMichael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.
Latest:
Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AMLGeoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Dr. Markowski on the Evaluation of Sabizabulin in mCRPCMark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Latest:
AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle ForwardLeland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Latest:
Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate CancerSaum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell LymphomaMany people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Latest:
Dr. Caimi on the FDA Approval of Loncastuximab Tesirine in R/R Large B-Cell LymphomaPaolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine-lpyl in relapsed/refractory large B-cell lymphoma.
Latest:
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian CancerDomenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator in combination with nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum resistant ovarian cancer.
Latest:
Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast CancerChristine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.
Latest:
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural IndianaResearchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Latest:
Dr. Ip on the Utility of Investigational Treatments for COVID-19 in OncologyAndrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.
Latest:
Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRCDavid Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.
Latest:
Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRCJulia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.
Latest:
Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian CancerMartin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.
Latest:
Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline GliomasDr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
Latest:
Dr. Hillmen on Results With Acalabrutinib in CLLPeter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.
Latest:
Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLCMitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Latest:
Dr Bhatnagar on Survival Outcomes With MRD Negativity in AMLBhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.
